Root Financial Partners’s Viridian Therapeutics VRDN Stock Holding History

Root Financial Partners’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.09K	Buy	+53	New	+$1.13K	﹤0.01%	2917

Other funds holding VRDN

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

AMI Asset Management Los Angeles, California $1.74B AUM 24.77% 1-Year Est. Return

OpenArc Corporate Advisory Atlanta, Georgia $8.86B AUM 19.31% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Root Financial Partners's VRDN Position: Q3 2026 in Review

Root Financial Partners opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 53 shares worth $1.09K. The stake represents ﹤0.01% of the portfolio and ranks #2917 among its holdings.

16 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

Root Financial Partners held 53 shares of Viridian Therapeutics worth $1.09K as of Q3 2026.
Viridian Therapeutics was a new Root Financial Partners position in Q3 2026.
Viridian Therapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q3 2026, its #2917 holding.
16 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Root Financial Partners's 13F filing for Q3 2026, filed 21 Oct 2026.